| Literature DB >> 28049505 |
Takashi Kobayashi1, Naohisa Miyakoshi2, Toshiki Abe3, Eiji Abe3, Kazuma Kikuchi3, Yoichi Shimada2, Seiko Matsumoto4, Shin Fukui5.
Abstract
BACKGROUND: Spinal metastasis is considered to have a worse prognosis in lung cancer than in other cancers, but recent clinical studies report improved overall survival of lung cancer. We compared the postoperative prognoses of vertebral metastatic tumors from lung with other types of cancer.Entities:
Keywords: Lung cancer; Metastatic vertebral tumor; Prognosis; Revised Tokuhashi score; Survival period
Mesh:
Year: 2017 PMID: 28049505 PMCID: PMC5209804 DOI: 10.1186/s13256-016-1157-3
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Modified Tokuhashi score
| Prognosis parameter | Score |
|---|---|
| General condition | |
| Poor (performance status 10–40%) | 0 |
| Moderate (performance status 50–70%) | 1 |
| Good (performance status 80–100%) | 2 |
| Number of bone metastases outside spine | |
| >2 | 0 |
| ≤2 | 1 |
| 0 | 2 |
| Metastasis to major organs | |
| Non-removable | 0 |
| Removable | 1 |
| None | 2 |
| Primary site | |
| Lung, osteosarcoma, stomach, bladder, esophagus, pancreas | 0 |
| Liver, gallbladder, unidentified | 1 |
| Other | 2 |
| Kidney, uterus | 3 |
| Rectum | 4 |
| Thyroid, breast, prostate, carcinoid tumor | 5 |
| Palsy | |
| Complete (Frankel A, B) | 0 |
| Incomplete (Frankel C, D) | 1 |
| None (Frankel E) | 2 |
Patient profiles
| Age (years) | Sex | Primary tumor type | Revised Tokuhashi score | Complication | Survival period (month) | Preoperative Frankel scorea | Postoperative Frankel scorea | Initial stageb | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General condition | Extraspinal bone metastases | Vertebral metastases | Internal organ | Primary site | Palsy | Tokuhashi score | |||||||||
| LK | |||||||||||||||
| 1 | 78 | f | Lung | 0 | 2 | 0 | 2 | 0 | 1 | 5 | 9 | C | D | 3 | |
| 2 | 81 | f | Lung | 0 | 2 | 1 | 2 | 0 | 1 | 6 | 35 | C | D | 4 | |
| 3 | 87 | f | Lung | 0 | 2 | 2 | 0 | 0 | 1 | 5 | 4 | C | D | 1 | |
| 4 | 72 | m | Lung | 0 | 2 | 0 | 2 | 0 | 1 | 5 | 3 | C | D | 4 | |
| 5 | 60 | f | Lung | 1 | 2 | 1 | 2 | 0 | 1 | 7 | 26 | D | D | 4 | |
| 6 | 86 | f | Lung | 0 | 2 | 0 | 2 | 0 | 1 | 5 | 12 | C | D | 4 | |
| 7 | 82 | m | Lung | 0 | 1 | 0 | 0 | 0 | 0 | 1 | infection | 1 | A | A | 3 |
| 8 | 72 | m | Lung | 0 | 1 | 2 | 2 | 0 | 1 | 6 | 3 | C | C | 4 | |
| 9 | 65 | m | Lung | 1 | 2 | 0 | 0 | 0 | 1 | 4 | 8 | C | D | 4 | |
| 10 | 69 | f | Lung | 0 | 1 | 0 | 2 | 0 | 1 | 4 | 7 | C | D | 4 | |
| Average | 75.2 ± 9.1 | 0.2 ± 0.4 | 1.7 ± 0.5 | 0.6 ± 0.8 | 1.4 ± 1.0 | 0 | 0.9 ± 0.3 | 4.8 ± 1.6 | 10.8 ± 11.1 | ||||||
| PB | |||||||||||||||
| 11 | 76 | m | Prostate | 0 | 2 | 2 | 2 | 5 | 1 | 12 | 62 | C | D | 4 | |
| 12 | 74 | m | Prostate | 1 | 2 | 1 | 2 | 5 | 1 | 12 | 11 | D | D | 3 | |
| 13 | 68 | m | Thyroid | 1 | 2 | 2 | 2 | 5 | 1 | 13 | 53 | D | D | 4 | |
| 14 | 84 | f | Breast | 0 | 2 | 1 | 2 | 5 | 1 | 11 | 44 | C | D | 1 | |
| 15 | 55 | f | Breast | 1 | 0 | 2 | 2 | 5 | 1 | 11 | 40 | D | D | 4 | |
| 16 | 70 | m | Prostate | 0 | 1 | 2 | 2 | 5 | 0 | 10 | 24 | B | D | 4 | |
| 17 | 72 | m | Prostate | 1 | 2 | 0 | 2 | 5 | 1 | 11 | infection | 27 | D | D | 4 |
| 18 | 66 | f | Thyroid | 1 | 2 | 1 | 2 | 5 | 1 | 12 | 26 | D | D | 4 | |
| 19 | 88 | m | Prostate | 0 | 2 | 0 | 2 | 5 | 0 | 9 | 10 | A | A | 4 | |
| 20 | 62 | f | Breast | 2 | 2 | 2 | 2 | 5 | 1 | 14 | 26 | D | D | 4 | |
| 21 | 58 | m | Prostate | 0 | 2 | 0 | 0 | 5 | 1 | 8 | 3 | C | D | 4 | |
| 22 | 73 | m | Prostate | 0 | 1 | 0 | 2 | 5 | 1 | 9 | 5 | C | D | 4 | |
| Average | 70.5 ± 9.7 | 0.6 ± 0.7 | 1.7 ± 0.7 | 1.1 ± 0.9 | 1.8 ± 0.6 | 5 | 0.8 ± 0.4 | 11.0 ± 1.8 | 27.6 ± 19.0 | ||||||
| OT | |||||||||||||||
| 23 | 71 | f | Rectum | 0 | 2 | 2 | 0 | 4 | 1 | 9 | 19 | D | D | 2 | |
| 24 | 76 | m | Kidney | 0 | 2 | 2 | 2 | 3 | 1 | 10 | 8 | D | D | 1 | |
| 25 | 71 | m | Kidney | 0 | 2 | 0 | 0 | 3 | 1 | 6 | 7 | C | D | 4 | |
| 26 | 83 | m | Rhabdomyosarcoma | 0 | 2 | 2 | 2 | 2 | 1 | 9 | 3 | C | C | 4 | |
| 27 | 78 | m | Kidney | 0 | 2 | 0 | 2 | 3 | 1 | 8 | infection | 5 | C | C | 4 |
| 28 | 87 | m | Unknown | 0 | 2 | 2 | 2 | 1 | 1 | 8 | 8 | C | D | 4 | |
| 29 | 62 | m | Colon | 0 | 2 | 0 | 0 | 2 | 1 | 5 | 2 | C | C | 4 | |
| 30 | 70 | m | Colon | 0 | 1 | 1 | 0 | 2 | 1 | 5 | 10 | D | D | 3 | |
| 31 | 79 | f | Multiple myeloma | 0 | 2 | 0 | 2 | 2 | 1 | 7 | 9 | C | C | 4 | |
| Average | 75.2 ± 7.6 | 0 | 1.9 ± 0.3 | 1.0 ± 1.0 | 1.1 ± 1.1 | 2.4 ± 0.9 | 1 | 7.4 ± 1.8 | 7.9 ± 5.0 | ||||||
LK lung cancer group, PB prostate, breast, or thyroid cancer group, OT other cancers group, m male, f female
aFrankel scores: A, complete neurological injury; B, preserved sensation only; C, preserved motor, nonfunctional; D, preserved motor, functional; E, normal (no neurological injury)
bInitial stage: 1, localized; 2, early locally advanced; 3, late locally advanced; 4, metastasized
Fig. 1Survival curves of patients with spinal metastases from lung (LK) versus prostate, breast, or thyroid primary tumor (PB) versus other cancers (OT). The postoperative survival period differed significantly among the three groups (P = 0.00). Pairwise comparisons using the log rank test revealed the survival period of the LK group to be significantly shorter than that of the PB group (P = 0.01), but there was no difference between the LK and OT groups